Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada.
Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
J Virol. 2018 Aug 16;92(17). doi: 10.1128/JVI.00422-18. Print 2018 Sep 1.
Type I interferon inhibits viruses through inducing the expression of antiviral proteins, including the myxovirus resistance (Mx) proteins. Compared to the human MxA protein, which inhibits a wide range of viruses, the MxB protein has been reported to specifically inhibit primate lentiviruses, including HIV-1, and herpesviruses. Further, the role of endogenous MxB in alpha interferon-mediated inhibition of HIV-1 infection was questioned by a recent study showing that MxB knockout did not increase the level of infection by HIV-1 which carried the G protein of vesicular stomatitis virus (VSV), allowing infection of CD4-negative HT1080 cells. In order to further examine the anti-HIV-1 activity of endogenous MxB, we have used CRISPR/Cas9 to deplete MxB in different cell lines and observed a substantial restoration of HIV-1 infection in the presence of alpha interferon treatment. However, this rescue effect of MxB knockout became much less pronounced when infection was performed with HIV-1 carrying the VSV G protein. Interestingly, a CRISPR/Cas9 knockout screen of alpha interferon-stimulated genes in U87-MG cells revealed that the genes for interferon-induced transmembrane protein 2 (IFITM2) and IFITM3 inhibited VSV G-pseudotyped HIV-1 much more strongly than the rest of the genes tested, including the gene for MxB. Therefore, our results demonstrate the importance of MxB in alpha interferon-mediated inhibition of HIV-1 infection, which, however, can be underestimated if infection is performed with VSV G protein-pseudotyped HIV-1, due to the high sensitivity of VSV G-mediated infection to inhibition by IFITM proteins. The results of this study reconcile the controversial reports regarding the anti-HIV-1 function of alpha interferon-induced MxB protein. In addition to the different cell types that may have contributed to the different observations, our data also suggest that VSV G protein-pseudotyped HIV-1 is much less inhibited by alpha interferon-induced MxB than HIV-1 itself is. Our results clearly demonstrate an important contribution of MxB to alpha interferon-mediated inhibition of HIV-1 in CD4 T cells, which calls for using HIV-1 target cells and wild-type virus to test the relevance of the anti-HIV-1 activity of endogenous MxB and other restriction factors.
I 型干扰素通过诱导抗病毒蛋白的表达来抑制病毒,包括粘病毒抗性 (Mx) 蛋白。与广泛抑制多种病毒的人 MxA 蛋白相比,MxB 蛋白已被报道可特异性抑制灵长类慢病毒,包括 HIV-1 和疱疹病毒。此外,最近的一项研究质疑内源性 MxB 在 α干扰素介导的 HIV-1 感染抑制中的作用,该研究表明,MxB 敲除并未增加携带水疱性口炎病毒 (VSV) G 蛋白的 HIV-1 的感染水平,从而允许 CD4 阴性 HT1080 细胞感染。为了进一步研究内源性 MxB 对 HIV-1 的抗病毒活性,我们使用 CRISPR/Cas9 敲除不同细胞系中的 MxB,并观察到在 α干扰素处理存在下 HIV-1 感染的大量恢复。然而,当用携带 VSV G 蛋白的 HIV-1 进行感染时,MxB 敲除的这种挽救效应变得不那么明显。有趣的是,在 U87-MG 细胞中对 α干扰素刺激基因的 CRISPR/Cas9 敲除筛选显示,干扰素诱导跨膜蛋白 2 (IFITM2) 和 IFITM3 的基因比测试的其他基因更强烈地抑制 VSV G 假型化的 HIV-1,包括 MxB 基因。因此,我们的结果表明 MxB 在 α 干扰素介导的 HIV-1 感染抑制中很重要,但如果用 VSV G 蛋白假型化的 HIV-1 进行感染,由于 VSV G 介导的感染对 IFITM 蛋白的抑制非常敏感,这种作用可能被低估。这项研究的结果调和了关于 α 干扰素诱导的 MxB 蛋白抗 HIV-1 功能的有争议的报告。除了可能导致不同观察结果的不同细胞类型外,我们的数据还表明,与 HIV-1 本身相比,α 干扰素诱导的 MxB 对 VSV G 蛋白假型化的 HIV-1 的抑制作用要小得多。我们的结果清楚地表明 MxB 对 CD4 T 细胞中 α 干扰素介导的 HIV-1 抑制有重要贡献,这就要求使用 HIV-1 靶细胞和野生型病毒来测试内源性 MxB 和其他限制因子的抗 HIV-1 活性的相关性。